Association of Baseline Serum Soluble Tumour Necrosis Factor Receptor Levels with the Response of Rheumatoid Arthritis to Janus Kinase Inhibitor Therapy.

IF 2.3 Q2 RHEUMATOLOGY
International Journal of Rheumatology Pub Date : 2024-04-27 eCollection Date: 2024-01-01 DOI:10.1155/2024/2898586
Takahiro Yoshikawa, Tetsuya Furukawa, Teppei Hashimoto, Naoto Azuma, Kiyoshi Matsui
{"title":"Association of Baseline Serum Soluble Tumour Necrosis Factor Receptor Levels with the Response of Rheumatoid Arthritis to Janus Kinase Inhibitor Therapy.","authors":"Takahiro Yoshikawa, Tetsuya Furukawa, Teppei Hashimoto, Naoto Azuma, Kiyoshi Matsui","doi":"10.1155/2024/2898586","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>The aim of this study was to investigate whether cytokines associated with tumour necrosis factor- (TNF-) <i>α</i> and interleukin- (IL-) 6 signalling could predict rheumatoid arthritis (RA) clinical remission (CR) with Janus kinase inhibitor (JAKinib) treatment using the Simplified Disease Activity Index (SDAI).</p><p><strong>Methods: </strong>Eighty-nine patients with RA treated with JAKinibs were enrolled, and their clinical data were collected retrospectively. CR was defined as an SDAI ≤ 3.3 after 6 months of treatment with JAKinib. The serum samples of 89 patients were analysed for IL-6, soluble IL-6 receptor (sIL-6R), soluble gp130 (spg130), and soluble TNF receptor- (sTNFR-) I and sTNFR-II titres.</p><p><strong>Results: </strong>There were no significant differences in the baseline clinical parameters between the CR and non-CR groups. Serum levels of IL-6, sIL-6R, and sgp130 were not significantly different; whereas, the serum sTNFR-I and sTNFR-II levels were significantly lower in the CR group. Univariate and multivariate logistic regression analysis showed that the baseline log sTNFR II values (OR: 0.002; <i>p</i> = 0.034) were predictors of CR.</p><p><strong>Conclusions: </strong>Patients with RA can be stratified prior to JAKinib administration using serum sTNFR-I and sTNFR-II levels but not serum IL-6 axis cytokine levels (IL-6, sIL-6R, and sgp130).</p>","PeriodicalId":51715,"journal":{"name":"International Journal of Rheumatology","volume":"2024 ","pages":"2898586"},"PeriodicalIF":2.3000,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11074879/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/2898586","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: The aim of this study was to investigate whether cytokines associated with tumour necrosis factor- (TNF-) α and interleukin- (IL-) 6 signalling could predict rheumatoid arthritis (RA) clinical remission (CR) with Janus kinase inhibitor (JAKinib) treatment using the Simplified Disease Activity Index (SDAI).

Methods: Eighty-nine patients with RA treated with JAKinibs were enrolled, and their clinical data were collected retrospectively. CR was defined as an SDAI ≤ 3.3 after 6 months of treatment with JAKinib. The serum samples of 89 patients were analysed for IL-6, soluble IL-6 receptor (sIL-6R), soluble gp130 (spg130), and soluble TNF receptor- (sTNFR-) I and sTNFR-II titres.

Results: There were no significant differences in the baseline clinical parameters between the CR and non-CR groups. Serum levels of IL-6, sIL-6R, and sgp130 were not significantly different; whereas, the serum sTNFR-I and sTNFR-II levels were significantly lower in the CR group. Univariate and multivariate logistic regression analysis showed that the baseline log sTNFR II values (OR: 0.002; p = 0.034) were predictors of CR.

Conclusions: Patients with RA can be stratified prior to JAKinib administration using serum sTNFR-I and sTNFR-II levels but not serum IL-6 axis cytokine levels (IL-6, sIL-6R, and sgp130).

血清可溶性肿瘤坏死因子受体基线水平与类风湿性关节炎对 Janus 激酶抑制剂疗法反应的关系
目的:本研究旨在探讨与肿瘤坏死因子(TNF-)α和白细胞介素(IL-)6信号相关的细胞因子是否能利用简化疾病活动指数(SDAI)预测类风湿性关节炎(RA)在接受Janus激酶抑制剂(JAKinib)治疗后的临床缓解(CR):招募了89名接受JAKinibs治疗的RA患者,并回顾性地收集了他们的临床数据。使用JAKinib治疗6个月后,SDAI≤3.3即为CR。对89名患者的血清样本进行了IL-6、可溶性IL-6受体(sIL-6R)、可溶性gp130(spg130)、可溶性TNF受体(sTNFR-)I和sTNFR-II滴度分析:CR 组和非 CR 组的基线临床参数无明显差异。血清中 IL-6、sIL-6R 和 sgp130 的水平无明显差异;而 CR 组血清中 sTNFR-I 和 sTNFR-II 的水平明显较低。单变量和多变量逻辑回归分析显示,sTNFR II 的基线对数值(OR:0.002;P = 0.034)是预测 CR 的因素:结论:使用血清sTNFR-I和sTNFR-II水平,而非血清IL-6轴细胞因子水平(IL-6、sIL-6R和sgp130),可在服用JAKinib前对RA患者进行分层。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.40
自引率
0.00%
发文量
9
审稿时长
24 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信